| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Investigation of the Traditional Algorithm-Based Designs for Phase 1 Cancer Clinical Trials
|
Kang, Seung-Ho
|
|
|
36 |
4 |
p. 865-873
|
artikel
|
| 2 |
Associating Genes to Drug Response
|
Katz, David A.
|
|
|
36 |
4 |
p. 751-761
|
artikel
|
| 3 |
Building a Computerized Herbal Substance Register for Implementation and Use in the World Health Organisation International Drug Monitoring Programme
|
Fucik, Helena
|
|
|
36 |
4 |
p. 839-854
|
artikel
|
| 4 |
Data Normalization Techniques and Autocoding Algorithms for The Medical Dictionary for Regulatory Activities (MedDRA)
|
Tucker, Mike Don
|
|
|
36 |
4 |
p. 927-933
|
artikel
|
| 5 |
Design and Evaluation of the Pharmacoinformatics Course at a Pharmacy School in Malaysia
|
Rahman, Ab Fatah Ab
|
|
|
36 |
4 |
p. 783-789
|
artikel
|
| 6 |
Dose Spacing in Early Dose Response Clinical Trial Designs
|
Hamlett, Anthony
|
|
|
36 |
4 |
p. 855-864
|
artikel
|
| 7 |
Establishing Shelf Life, Expiry Limits, and Release Limits
|
Murphy, John R.
|
|
|
36 |
4 |
p. 769-781
|
artikel
|
| 8 |
Is It Possible to Claim Efficacy if One of Two Trials is Significant While the other Just Shows a Trend?
|
Rosenkranz, Gerd
|
|
|
36 |
4 |
p. 875-879
|
artikel
|
| 9 |
Managing Medical Information Effectively Facilitates the Quality and Time to Delivering the Final Product
|
Cowlrick, Ivor
|
|
|
36 |
4 |
p. 825-829
|
artikel
|
| 10 |
Naming, Classification, And Trademark Selection: Implications For Market Success Of Pharmaceutical Products
|
Gantner, Florian
|
|
|
36 |
4 |
p. 807-824
|
artikel
|
| 11 |
New Directions in Pharmacoeconomic Research: The Next Step
|
Ruchlin, Hirsch S.
|
|
|
36 |
4 |
p. 909-917
|
artikel
|
| 12 |
Nonparametric Identification of the Minimum Effective Dose
|
Neuhauser, Markus
|
|
|
36 |
4 |
p. 881-888
|
artikel
|
| 13 |
Outcomes Research Support of Potential Blockbuster Drugs
|
Lapuerta, Pablo
|
|
|
36 |
4 |
p. 919-926
|
artikel
|
| 14 |
Placebo Controlled Clinical Trials are as Ethical as Active Controlled Trials Even if Effective Therapies Exist
|
Lin, Yeong-Liang
|
|
|
36 |
4 |
p. 739-741
|
artikel
|
| 15 |
Review 2001: The Future of European Pharmaceutical Legislation
|
Lamb, Louise
|
|
|
36 |
4 |
p. 899-907
|
artikel
|
| 16 |
Sponsors’ Experiences with Site Management Organizations in Japan
|
Miyazaki, Koichi
|
|
|
36 |
4 |
p. 763-768
|
artikel
|
| 17 |
Technological Innovations in Professional Services
|
Klein, Erik W.
|
|
|
36 |
4 |
p. 791-805
|
artikel
|
| 18 |
The Attitude of Pharmaceutical Industry Research Scientists to Browsing and Publishing on Internet Preprint and E-Print Servers
|
Miranda, Giovanna F.
|
|
|
36 |
4 |
p. 831-837
|
artikel
|
| 19 |
The Cultural Framework for the Ethical Review of Clinical Research in Latin America
|
Cavazos, Nora
|
|
|
36 |
4 |
p. 727-737
|
artikel
|
| 20 |
The Genomics Revolution: Will this Mean a Resurgence of Customized Prescriptions?
|
Ruano-Ravina, A.
|
|
|
36 |
4 |
p. 725-726
|
artikel
|
| 21 |
The Impact of the Implementation of the International Conference on Harmonisation Essential Documents on Investigator Sites
|
Icart, Luis Peña
|
|
|
36 |
4 |
p. 743-750
|
artikel
|
| 22 |
The Regulation of Dietary Supplements in the Republic of Armenia
|
Gabrielyan, Emil
|
|
|
36 |
4 |
p. 889-897
|
artikel
|
Tijdschrift beschrijving